Win Medica is pleased to announce the launch of the first long-acting Bio-Similar Filgrastim in Greece. The drug is indicated for the reduction of the duration of neutropenia and the incidence of febrile neutropenia in adult patients following cytotoxic chemotherapy for the treatment of malignant disease. The long-acting action of the drug is due to the addition of a polyethylene glycol (PEG) molecule to Filgrastim. Phylrastim increases the size of the molecule, reduces the clearance of the drug and significantly prolongs its duration of action. It is administered as a single dose per chemotherapy cycle and therefore has less inconvenience for the Patient who would need, in comparison, as studies show, many more daily administrations of Filgrastim.
It is important to emphasize that Bio-like Pegylated Filgrastim, is a high quality biotechnological product, which is expected to reliably meet the needs of Patients and provide significant savings for the Health System.
The Director of the C Oncology Clinic of the Metropolitan Hospital Dr. Vasilios Barbounis said. This drug is expected to offer the patient a safe and effective weapon against febrile neutropenia caused by chemotherapy, drastically reducing with a single administration the morbidity and risks of neutropenia, as well as the discomfort of multiple injections. The medical community will rely on its high technology and proven safety. The national health system will save resources and the community as a whole will have access to the commodity of pharmaceutical care.”
Win Medica President and CEO Marios Kosmidis said: “We are particularly proud of the launch of the 1st Bio-Similar Long-Acting Filgrastim in Greece. We will continue to offer the Medical Community therapeutic options with high efficacy, quality and safety. At Win Medica we remain true to our vision of continuous improvement in the health and quality of life of our patients.”
About Win Medica
Win Medica is one of the fastest growing pharmaceutical companies in Greece, in the field of primary health and hospital care, with a modern strategy serving the improvement of Health, the Patient’s access to treatments and the saving of resources. The areas of activity include originator medicines, high value-added generic and differentiated medicines, biotechnology medicines, medical devices and non-prescription medicines. Product and service quality is Win Medica’s key roadmap. With a focus on caring for People, Win Medica produces, promotes and distributes safe, quality medicines that improve the quality of life of Patients, investing steadily in research and supporting distinguished scientists of our country.
About Accord Healthcare
Accord Healthcare, the licensee of this drug, is an established generic and biotechnology company that is active in the development, production and distribution of pharmaceutical products in over 80 countries around the world, including the United States and Canada. It started its commercial activity in Europe in 2008 and currently has over 9,300 marketing authorisations across the European continent. It offers vital medicines at affordable prices, for healthcare systems and Patients. Its approach is flexible and innovative to always improve its products and Patients’ access to them.
For more information, please contact Win Medica, firstname.lastname@example.org, tel. 210-7488821.